Abbreviations:
technologycumulative, ovarian responsetraditional
MAY, RECRUITMENT
antral follicle countartificial reproductive technologycumulative live birth ratecontrolled ovarian stimulationcase report formErzhi Tianguiintention-to-treatin vitro fertilization-embryo transferluteal phase supportpoor ovarian responsetraditional Chinese medicinetrial monitoring committeeThe datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.The trial is ongoing. The recruitment began in May 2023 and is anticipated to be completed in June 2025.The ethics committee of the affiliated hospital of Shandong University of Traditional Chinese Medicine has reviewed and approved the study protocol (identifier: SDUTCMEZTG1104). And the other participating centers also provided written consent material.The authors have no conflicts of interest to disclose.The study is supported by the Youth Realistic Project of China Association of Chinese Medicine (2022-QNQSDEP-03). All funders will have no involvement in the study design, data collecting, data analysis, interpretation of the results, or manuscript writing.How to cite this article: Han Q-S, Zhou Y, Chen W, Song J-Y, Sun Z-G. The role of Erzhi Tiangui formula in expected poor ovarian responders undergoing in vitro fertilization-embryo transfer: A multicenter, randomized, double-blind, placebo-controlled trial. Medicine 2023;102:27(e34088).